Data / Federal awards / NAICS 541714 / Department of Health and Human Services
Department of Health and Human Services contracts under NAICS 541714 Research and Development in Biotechnology (except Nanobiotechnology): $5.9 billion to 563 recipients (FY2024 to FY2027)
Updated October 6, 2026. Source: USAspending.gov.
Department of Health and Human Services obligated $5.9 billion under NAICS 541714, Research and Development in Biotechnology (except Nanobiotechnology), across 1,502 contract awards to 563 named recipients in fiscal years 2024 to 2027. The largest recipients are ADVANCED TECHNOLOGY INTERNATIONAL ($1.8 billion), ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) ($356.9 million), AMGEN USA INC ($345.8 million). 20 opportunities under this code are open on SAM.gov now.
The request: Every federal contract awarded by Department of Health and Human Services under NAICS 541714, with the winner, the value and the period of performance. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every federal contract award on USAspending.gov and every open opportunity on SAM.gov, and this page is that reading. Ask for the awards in your niche and the winners, agencies, values and recompetes arrive in your sheet, CRM, Slack or agent as they are reported.
- Agency
- Department of Health and Human Services
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Contract awards
- 1,502
- Obligated
- $5.9 billion
- Named recipients
- 563
- Small business share of obligations
- 24%
- Full and open competition share
- 97%
- Set aside share
- 1%
- Latest action
- 2026-10-01
Open opportunities in this niche
The same code on SAM.gov, read each morning: 20 opportunities you can still respond to.
Incumbents at this agency
Ranked by dollars obligated in fiscal years 2024 to 2027.
| Recipient | Business size | Awards | Obligated | Share |
|---|---|---|---|---|
| ADVANCED TECHNOLOGY INTERNATIONAL | Other Than Small Business | 9 | $1.77 billion | 29.8% |
| ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) | Other Than Small Business | 3 | $356.9 million | 6.0% |
| AMGEN USA INC | Other Than Small Business | 2 | $345.8 million | 5.8% |
| START2 GROUP, INC. | Small Business | 1 | $227.1 million | 3.8% |
| PPD DEVELOPMENT LP | Other Than Small Business | 12 | $197.2 million | 3.3% |
| SIGA TECHNOLOGIES, INC. | Other Than Small Business | 1 | $167.7 million | 2.8% |
| SHIONOGI INC | Other Than Small Business | 1 | $156.1 million | 2.6% |
| BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL | Small Business | 2 | $147.4 million | 2.5% |
| MAPP BIOPHARMACEUTICAL, INC. | Other Than Small Business | 5 | $136.1 million | 2.3% |
| KALEO, INC. | Small Business | 2 | $129.3 million | 2.2% |
| EMERGENT BIODEFENSE OPERATIONS LANSING LLC | Small Business | 1 | $86.9 million | 1.5% |
| BATTELLE MEMORIAL INSTITUTE | Other Than Small Business | 30 | $85.7 million | 1.4% |
| GLAXOSMITHKLINE, LLC | Other Than Small Business | 19 | $79.7 million | 1.3% |
| TECHNICAL RESOURCES INTERNATIONAL, INC. | Small Business | 15 | $78.2 million | 1.3% |
| OSSIUM HEALTH, INC. | Small Business | 1 | $69.9 million | 1.2% |
| GENENTECH INC | Other Than Small Business | 2 | $69.4 million | 1.2% |
| TRUSTEES OF BOSTON UNIVERSITY | Other Than Small Business | 1 | $65.8 million | 1.1% |
| CERUS CORPORATION | Small Business | 1 | $65.4 million | 1.1% |
| 4J THERAPEUTICS INC | Small Business | 1 | $63.1 million | 1.1% |
| VEDANTA BIOSCIENCES, INC. | Small Business | 1 | $63 million | 1.1% |
| PUBLIC HEALTH VACCINES LLC | Small Business | 1 | $60.4 million | 1.0% |
| EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | Other Than Small Business | 2 | $58.6 million | 1.0% |
| CIDARA THERAPEUTICS INC | Small Business | 1 | $58.1 million | 1.0% |
| LOCUS BIOSCIENCES INC | Other Than Small Business | 2 | $56.7 million | 1.0% |
| SANOFI VACCINES US INC. | Other Than Small Business | 15 | $56.7 million | 1.0% |
| MODEX THERAPEUTICS, INC | Other Than Small Business | 1 | $44.5 million | 0.7% |
| GE MEDICAL SYSTEMS INFORMATION TECHNOLOGIES, INC. | Other Than Small Business | 1 | $42.2 million | 0.7% |
| PARATEK PHARMACEUTICALS, INC | Small Business | 1 | $40.7 million | 0.7% |
| ABBOTT LABORATORIES | Other Than Small Business | 1 | $39.9 million | 0.7% |
| SEATTLE CHILDREN'S HOSPITAL | Other Than Small Business | 2 | $39.2 million | 0.7% |
| CEPHEID | Other Than Small Business | 1 | $37.2 million | 0.6% |
| PSYCHOGENICS INC. | Small Business | 2 | $36 million | 0.6% |
| VERICEL CORPORATION | Small Business | 1 | $34.9 million | 0.6% |
| SPECTRAL MD, INC. | Small Business | 1 | $31.7 million | 0.5% |
| INVIRSA, INC. | Small Business | 1 | $29.9 million | 0.5% |
| DUKE UNIVERSITY | Other Than Small Business | 15 | $28.3 million | 0.5% |
| BOOZ ALLEN HAMILTON INC | Other Than Small Business | 12 | $28.2 million | 0.5% |
| MELINTA THERAPEUTICS, LLC | Other Than Small Business | 1 | $27 million | 0.5% |
| FISHER BIOSERVICES INC | Other Than Small Business | 21 | $24.9 million | 0.4% |
| ALPHA GENESIS INC | Small Business | 5 | $24.8 million | 0.4% |
| RHO FEDERAL SYSTEMS DIVISION INC | Small Business | 1 | $24.3 million | 0.4% |
| EITR BIOLOGICS, INC. | Small Business | 1 | $23.4 million | 0.4% |
| THE BROAD INSTITUTE, INC | Other Than Small Business | 6 | $22.6 million | 0.4% |
| PATTERN BIOSCIENCE, INC. | Small Business | 1 | $22.5 million | 0.4% |
| SAPPHIROS LLC | Small Business | 1 | $22.4 million | 0.4% |
| OSIVAX | Other Than Small Business | 2 | $20.2 million | 0.3% |
| PRENOSIS, INC | Small Business | 1 | $20 million | 0.3% |
| THE CHARLES STARK DRAPER LABORATORY, INC. | Other Than Small Business | 3 | $19.2 million | 0.3% |
| CORIELL INSTITUTE FOR MEDICAL RESEARCH, INC. | Other Than Small Business | 1 | $19 million | 0.3% |
| SPERO THERAPEUTICS, INC. | Small Business | 1 | $18.2 million | 0.3% |
Offices buying
| Sub agency | Awards | Obligated |
|---|---|---|
| Office of Assistant Secretary for Preparedness and Response | 284 | $5.05 billion |
| National Institutes of Health | 955 | $778.3 million |
| Food and Drug Administration | 191 | $100.3 million |
| Centers for Disease Control and Prevention | 68 | $20 million |
| Health Resources and Services Administration | 3 | $2.1 million |
| Indian Health Service | 1 | $515,769 |
Obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2024 | $3.23 billion |
| FY2025 | $1.03 billion |
| FY2026 | $1.69 billion |
| FY2027 | $-354,810 |
Products and services bought
| Code | Product or service | Awards | Obligated |
|---|---|---|---|
| AN42 | Health R&d Services; Health Care - Other; Applied Research | 65 | $2.37 billion |
| AN13 | Health R&d Services; Health Care Services; Experimental Development | 149 | $1.42 billion |
| AN12 | Health R&d Services; Health Care Services; Applied Research | 307 | $633.9 million |
| 6505 | Drugs and Biologicals | 105 | $522.6 million |
| AN11 | Health R&d Services; Health Care Services; Basic Research | 409 | $411.9 million |
| AZ13 | R&d- Other Research and Development (advanced Development) | 4 | $92.9 million |
| AJ15 | General Science & Technology R&d Svcs; General Science & Technology; R&d Facilities & Maj Equip | 1 | $86.9 million |
| AN41 | Health R&d Services; Health Care - Other; Basic Research | 13 | $74.6 million |
Largest contract awards
| Award ID | Recipient | Agency | Type | NAICS | What it buys | Obligated in window | Award value | Starts | Ends | Place of performance | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 75A50123F61001 | ADVANCED TECHNOLOGY INTERNATIONAL | Department of Health and Human Services | Delivery Order | 541714 | OTA TASK ORDER 1 | $595,000,000 | $795,000,000 | September 28, 2023 | December 31, 2029 | Summerville, SC | usaspending.gov |
| 75A50124F61008 | ADVANCED TECHNOLOGY INTERNATIONAL | Department of Health and Human Services | Delivery Order | 541714 | OT TASK ORDER 8-RAPID PANDEMIC INFLUENZA AND EMERGING INFECTIOUS DISEASE VACCINE DEVELOPMENT AND RESPONSE CAPABILITY | $563,743,254 | $563,743,254 | June 14, 2024 | September 30, 2036 | Summerville, SC | usaspending.gov |
| 75A50122C00065 | AMGEN USA INC | Department of Health and Human Services | Definitive Contract | 541714 | TREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MAJOR CONCERN. | $344,956,700 | $839,875,190 | September 30, 2022 | September 29, 2032 | Newbury Park, CA | usaspending.gov |
| 75A50123F61003 | ADVANCED TECHNOLOGY INTERNATIONAL | Department of Health and Human Services | Delivery Order | 541714 | OT TASK ORDER 3 | $323,524,000 | $723,524,000 | September 29, 2023 | December 31, 2030 | Summerville, SC | usaspending.gov |
| 75A50126C00001 | ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) | Department of Health and Human Services | Definitive Contract | 541714 | STRATEGIC MARBURG ADVANCED RESEARCH AND DEVELOPMENT, PREPAREDNESS, REGISTRATION, EVALUATION AND PROCUREMENT (SMART-PREP) | $263,613,186 | $263,613,186 | May 8, 2026 | April 30, 2036 | Washington, DC | usaspending.gov |
| 75A50124C00012 | START2 GROUP, INC. | Department of Health and Human Services | Definitive Contract | 541714 | OTHER TRANSACTION: START2 GROUP, INC. (75A50124C00012) | $227,139,021 | $227,139,021 | April 10, 2024 | September 30, 2031 | Cambridge, MA | usaspending.gov |
| 75A50118C00019 | SIGA TECHNOLOGIES, INC. | Department of Health and Human Services | Definitive Contract | 541714 | PROCUREMENT AND LATE-STAGE DEVELOPMENT OF SMALLPOX ANTIVIRAL DRUG(S) IGF::OT::IGF | $167,743,809 | $626,506,870 | September 10, 2018 | August 30, 2029 | Corvallis, OR | usaspending.gov |
| 75A50126C00004 | SHIONOGI INC | Department of Health and Human Services | Definitive Contract | 541714 | LATE-STAGE DEVELOPMENT, FDA MARKETING AUTHORIZATION, PROCUREMENT, AND STOCKPILE OF ANTIBIOTICS FOR THE TREATMENT OF DRUG-RESISTANT SECONDARY | $156,103,541 | $156,103,541 | April 6, 2026 | March 10, 2036 | Florham Park, NJ | usaspending.gov |
| 75A50123F61004 | ADVANCED TECHNOLOGY INTERNATIONAL | Department of Health and Human Services | Delivery Order | 541714 | OT TASK ORDER 4 | $155,201,807 | $1,010,801,807 | September 29, 2023 | December 31, 2030 | Summerville, SC | usaspending.gov |
| 75A50124C00033 | BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL | Department of Health and Human Services | Definitive Contract | 541714 | THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA | $122,501,232 | $122,501,232 | September 30, 2024 | March 31, 2032 | Switzerland | usaspending.gov |
| 75A50124C00001 | PPD DEVELOPMENT LP | Department of Health and Human Services | Definitive Contract | 541714 | BARDA WILL IMPLEMENT A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 2 TRIAL IN THE US TO EVALUATE THE SAFETY AND EFFICACY | $117,399,278 | $117,399,278 | December 15, 2023 | September 30, 2030 | Wilmington, NC | usaspending.gov |
| 75A50124F61006 | ADVANCED TECHNOLOGY INTERNATIONAL | Department of Health and Human Services | Delivery Order | 541714 | OT TASK ORDER 6 - DXR2 | $100,000,000 | $100,000,000 | March 15, 2024 | June 16, 2027 | Summerville, SC | usaspending.gov |
| 75A50126C00010 | KALEO, INC. | Department of Health and Human Services | Definitive Contract | 541714 | THIS ACQUISITION WILL ALLOW BARDA TO INVEST PROJECT BIOSHIELD FUNDS FOR LATE-STAGE CLINICAL DEVELOPMENT, REGULATORY APPROVAL FOR 2-PAM AUTOI | $96,058,494 | $96,058,494 | September 30, 2026 | December 31, 2034 | Glen Allen, VA | usaspending.gov |
| 75A50123C00010 | ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) | Department of Health and Human Services | Definitive Contract | 541714 | THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT | $91,692,302 | $163,082,416 | December 29, 2022 | September 30, 2030 | Washington, DC | usaspending.gov |
| 75A50122C00047 | EMERGENT BIODEFENSE OPERATIONS LANSING LLC | Department of Health and Human Services | Definitive Contract | 541714 | CHIMERIX INC: AR&D FOR SMALLPOX ANTIVIRAL | $86,865,156 | $213,770,068 | August 29, 2022 | October 1, 2028 | Durham, NC | usaspending.gov |
| 75A50122C00061 | MAPP BIOPHARMACEUTICAL, INC. | Department of Health and Human Services | Definitive Contract | 541714 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES | $86,076,373 | $220,916,162 | September 30, 2022 | September 30, 2030 | San Diego, CA | usaspending.gov |
| 75N93024F00001 | PPD DEVELOPMENT LP | Department of Health and Human Services | Delivery Order | 541714 | NIAID CLINICAL SITE MONITORING (NCSM) | $73,196,564 | $73,196,564 | February 1, 2024 | January 31, 2027 | Wilmington, NC | usaspending.gov |
| 75A50124C00032 | OSSIUM HEALTH, INC. | Department of Health and Human Services | Definitive Contract | 541714 | BONE MARROW CRYO-BANKING TO TREAT ACUTE RADIATION SYNDROME IN A MASS-CASUALTY EMERGENCY | $69,935,347 | $69,935,347 | August 9, 2024 | November 30, 2029 | San Francisco, CA | usaspending.gov |
| 75A50118D00036 | GENENTECH INC | Department of Health and Human Services | IDC | 541714 | ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA | $68,304,864 | $636,607,100 | September 27, 2018 | usaspending.gov | ||
| 75A50122C00028 | TRUSTEES OF BOSTON UNIVERSITY | Department of Health and Human Services | Definitive Contract | 541714 | CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA | $65,780,000 | $150,780,000 | June 1, 2022 | May 31, 2029 | Boston, MA | usaspending.gov |
| 75A50124C00046 | CERUS CORPORATION | Department of Health and Human Services | Definitive Contract | 541714 | LICENSE PATHOGEN REDUCTION TECHNOLOGY (PRT) FOR RED BLOOD CELL (RBC) COMPONENTS TO REDUCE THE RISK OF TRANSFUSION-TRANSMITTED INFECTION (TTI | $65,358,564 | $65,358,564 | September 30, 2024 | September 30, 2031 | Concord, CA | usaspending.gov |
| 75A50124C00052 | 4J THERAPEUTICS INC | Department of Health and Human Services | Definitive Contract | 541714 | THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO DEMONSTRATE THE VERSATILITY AND EFFICACY OF OUR PROGRAMMABLE ANTIVIRAL TECHNOLOGY PLATFORM BY A | $63,083,814 | $63,083,814 | September 30, 2024 | March 31, 2032 | Palo Alto, CA | usaspending.gov |
| 75A50120C00177 | VEDANTA BIOSCIENCES, INC. | Department of Health and Human Services | Definitive Contract | 541714 | TO DEVELOP MEDICAL COUNTERMEASURES (MCMS) THAT TREAT ANTIBIOTIC RESISTANT INFECTIONS. | $63,000,000 | $99,146,088 | September 28, 2020 | August 31, 2027 | Boston, MA | usaspending.gov |
| 75A50119C00022 | PUBLIC HEALTH VACCINES LLC | Department of Health and Human Services | Definitive Contract | 541714 | ADVANCED RESEARCH AND DEVELOPMENT OF RVSV-MARV VACCINE. | $60,426,909 | $89,026,883 | February 1, 2019 | January 31, 2029 | Cambridge, MA | usaspending.gov |
| 75A50123C00037 | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | Department of Health and Human Services | Definitive Contract | 541714 | MEDICAL COUNTERMEASURES (MCM) THAT CAN BE DEPLOYED IN THE EVENT OF A FILOVIRUS OUTBREAK ARE A CRUCIAL COMPONENT TO THE UNITED STATES GOVERNM | $58,589,653 | $237,127,358 | July 31, 2023 | July 29, 2033 | Gaithersburg, MD | usaspending.gov |
Public U.S. federal spending data (U.S. Department of the Treasury). Obligations are the contract actions dated in fiscal years 2024 to 2027 of the USAspending.gov award archive of 2026-10-06; a contract's total value is its current value as USAspending reports it, including earlier years. Recipients are matched on their SAM.gov UEI, never on the name, and are shown as the government prints them. Sole proprietorships and opted-out entities count in the totals and are not named. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.